UK markets closed
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • FTSE 250

    17,168.34
    +377.94 (+2.25%)
     
  • AIM

    806.38
    +7.99 (+1.00%)
     
  • GBP/EUR

    1.1381
    +0.0057 (+0.50%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • BTC-GBP

    17,341.32
    -60.37 (-0.35%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • DOW

    28,725.51
    -500.10 (-1.71%)
     
  • CRUDE OIL

    79.74
    -1.49 (-1.83%)
     
  • GOLD FUTURES

    1,668.30
    -0.30 (-0.02%)
     
  • NIKKEI 225

    25,937.21
    -484.84 (-1.83%)
     
  • HANG SENG

    17,222.83
    +56.96 (+0.33%)
     
  • DAX

    12,114.36
    +138.81 (+1.16%)
     
  • CAC 40

    5,762.34
    +85.47 (+1.51%)
     

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

·5-min read

Gilead Sciences, Inc. GILD reported strong second-quarter results driven by continued solid demand for its HIV portfolio with further share growth for flagship therapy Biktarvy, and oncology revenues driven by cell therapy and Trodelvy.  Sales of COVID-19 treatment Veklury (remdesivir) declined as predicted but came in better than expected.

Consequently, management upped its revenue guidance.

Gilead’s stock has lost 18% so far in the year compared with the industry's decline of 22.6%.

 

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The company reported earnings of $1.58 per share in the quarter, which beat the Zacks Consensus Estimate of $1.51 but were down from $1.81 in the year-ago quarter.

The year-over year decline was primarily due to upfront payment for Dragonfly collaboration and Biktarvy [bictegravir 50mg/emtricitabine 200mg (FTC)/tenofovir alafenamide 25mg (TAF)]-related royalty expense that began in the first quarter of 2022.

Total revenues of $6.3 billion surpassed the Zacks Consensus Estimate of $5.9 billion and increased 1% from the year-ago quarter due to higher sales of HIV and oncology products, offset partially by decreased sales of Veklury and hepatitis C virus (HCV) products.

Quarter in Detail

Total product sales were flat at $6.1 billion in the quarter under review. Excluding Veklury, product sales increased 7% year over year to $5.7 billion due to growth in the HIV, Cell Therapy and Trodelvy (sacituzumab govitecan-hziy) businesses.

HIV product sales increased 7% to $4.2 billion, driven by growth in demand for flagship HIV therapy Biktarvy and changes in channel mix leading to higher average realized price.

Biktarvy sales increased 28% year over year to $2.5 billion due to higher demand and channel mix. Descovy (FTC 200mg/TAF 25mg) sales increased 6% to $460 million driven by channel mix and increased demand.  The Zacks Consensus Estimate for sales of Biktarvy and Descovy were $2.3 billion and $444 million, respectively.

However, HCV product sales decreased 18% to $448 million, affected by channel mix, leading to lower average realized price and a fewer patient starts.
Hepatitis B virus (HBV) and hepatitis delta virus (HDV) product sales decreased 1% to $234 million. Vemlidy (TAF 25mg) sales decreased 3%, primarily due to China Volume Based Procurement update.

Cell Therapy product sales increased 68% to $368 million. Yescarta sales increased 66% to $295 million, driven by demand for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and strong uptake in R/R indolent follicular lymphoma in the United States. Tecartus sales totaled $73 million, driven by demand for R/R mantle cell lymphoma (MCL) in the United States and Europe and for adult patients with R/R B-cell precursor acute lymphoblastic leukemia (ALL) in the United States.

Breast cancer drug Trodelvy’s sales increased 79% to $159 million, reflecting uptake in both the second- and third-line settings for the treatment of metastatic triple-negative breast cancer (TNBC) in the United States and Europe as well as for metastatic urothelial cancer in the United States.

Veklury sales decreased 46% to $445 million due to lower demand as hospitalization rates declined in most regions.

Adjusted product gross margin was 85.6% compared with 86.4% in the year-ago period. Research & development expenses were $1.1 billion, up 10% year over year. SG&A expenses were $1.3 billion, up 18.1%.

2022 Guidance Updated

Product sales are now projected between $24.5 billion and $25.0 billion (earlier projection- $23.8–$24.3 billion). Total product sales, excluding Veklury, are expected to be $22.0 billion to $22.5 billion (previous projection: $21.8–$22.3 billion). Total Veklury sales are now estimated at around $2.5 billion (earlier estimate: $2 billion). Earnings per share are expected in the range of $6.35-$6.75 (previous estimate: $6.20-$6.70). The Zacks Consensus Estimate for sales and earnings per share is pegged at $24.67 billion and $6.60, respectively.

Other Updates

The FDA has accepted the company’s new drug application (NDA) for experimental candidate lenacapavir. The company is seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for treating heavily treatment-experienced (HTE) people with multi-drug-resistant (MDR) HIV-1 infection. The agency has set a target action date of Dec 27, 2022.

Gilead entered into a strategic research collaboration with Dragonfly to advance a number of novel natural killer cell engager-based immunotherapies for oncology and inflammation indications.  Per the terms, Gilead will receive an exclusive worldwide license for investigational DF7001 along with options to license several additional NK cell engager programs.

Gilead Sciences, Inc. Price, Consensus and EPS Surprise

Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise

Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote

Our Take

Gilead’s second-quarter results were better than expected, driven by strong Biktarvy sales.

Gilead is making efforts to develop its oncology business to diversify its revenue base as competition is stiff in the HIV business from the likes of GlaxoSmithKline GSK.

Glaxo’s HIV franchise recorded 7% growth in the second quarter.  Growth was driven by new HIV products Dovato, Cabenuva, Rukobia, Juluca and Apretude and a favorable U.S. pricing mix.

Zacks Rank & Stocks to Consider

Gilead currently carries a Zacks Rank #3 (Hold).  A couple of better-ranked stocks are Alkermes ALKS and Dynavax  DVAX, both carrying Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ALKS’ earnings estimates for 2022 reversed from a loss of 14 cents to earnings of 20 cents in the past seven days. Alkermes surpassed earnings in all the trailing four quarters, the average being 325.48%.

Dynavax’s earnings estimates have increased to $1.15 from $1.14 for 2022 over the past 60 days. Earnings of Dynavax have surpassed estimates in two of the trailing four quarters.
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
 
Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report
 
Alkermes plc (ALKS) : Free Stock Analysis Report
 
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research